Disc Medicine received a Complete Response Letter from the FDA on February 13, 2026, rejecting its new drug application for bitopertin due to uncertainties needing more evidence. Following this, the company's stock price fell 22%. The Rosen Law Firm is investigating potential securities claims and preparing a class action lawsuit to recover investor losses, offering compensation without upfront fees. Investors who purchased Disc Medicine securities may join the class action for possible compensation.
Micron Technology's stock dropped nearly 13% over two days, marking its worst decline since April 2025, driven by overheated technical indicators and broader semiconductor sector weakness. Despite the sharp pullback, the stock remains significantly a...
Hyperscale Data, an AI data center company focused on Bitcoin, announced monthly cash dividends of $0.2708333 per share for its 13.00% Series D preferred stock and $0.20833 per share for its 10.00% Series E preferred stock. The dividends will be paid...
Vishay Intertechnology announced a quarterly dividend of $0.10 per share for both common and Class B common stock. The dividend will be paid on June 29, 2026, to shareholders recorded by June 18, 2026. Future dividends will depend on board approval. ...
Valley National Bancorp announced its regular quarterly dividends for preferred and common stockholders, payable in late June and early July 2026. The preferred stock dividends vary by series, with payments ranging from approximately $0.48 to $0.52 p...
Cytokinetics granted stock options for 20,807 shares and 13,793 restricted stock units (RSUs) to eight new employees who started in April and May 2026. The RSUs vest over three years, while the stock options vest over four years with an exercise pric...
